Novo Nordisk A/S (NYSE:NVO) is highlighted as one of the most profitable healthcare stocks to buy, with BMO Capital raising its price target to $57. Despite flat prescription trends for weight loss drug Wegovy in Q4 2025, the firm reduced its 2025 sales estimate. Reuters reported over 18,000 Wegovy prescriptions in the U.S. in the first week post-launch, with positive early data. Novo Nordisk, founded in 1923, operates in Diabetes and Obesity Care and Rare Disease segments. While NVO shows investment potential, consider other AI stocks for greater upside and less risk.

Source: https://finance.yahoo.com/quote/NVO

Read more at Yahoo Finance: BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures